BTSG Shorts Retreat as Morgan Stanley Lifts Target to $71

What is driving the short unwind is easy to identify: the May 1 earnings print. BTSG jumped 11.6% on the day and followed through with a 14.3% gain over the following five sessions — the kind of move that forces bearish positions to cover. Raised full-year guidance cemented the re-rating. The Street responded immediately. Morgan Stanley, Wells Fargo, Mizuho, TD Cowen, Keybanc, Stephens, BMO Capital, and BTIG all raised price targets in the days after the report, every one of them maintaining positive ratings. Morgan Stanley's Erin Wright followed up again this week — on June 2 — lifting her target a second time, from $62 to $71, keeping an Overweight. The consensus mean target is now $62, but with the stock already at $59.34 and Erin Wright's updated number at $71, the upside debate has shifted from "can it get there?" to "how far above consensus does it go?" No analyst has cut the stock. The direction of travel on the Street is unanimously higher targets.

Valuation is the bear case in a nutshell. The trailing P/E is optically punishing — but the reported net income figure includes items that inflate it. EV/EBITDA at roughly 17x is far more meaningful for a healthcare services business with thin margins. Revenue grew 25.6% year-on-year last quarter. EBITDA margins are lean at 4.4%, and gross margins sit at 13.3% — both below analyst estimates, which feeds the bear argument that BrightSpring is a volume story more than a profitability story. Net debt of $1.8bn against trailing EBITDA of around $640m implies leverage in the 2.5x range, manageable but not comfortable. The bears' concern is that the high-revenue, low-margin model is vulnerable to reimbursement pressure or labor cost inflation — and a debt/equity ratio above 135% leaves little cushion if conditions deteriorate.

The institutional picture adds an important overlay. KKR — the parent company and dominant shareholder at just over 20% — trimmed nearly 19.7 million shares on March 4, a block sale at $40.96 that raised over $807m. CEO Jon Rousseau sold alongside that transaction, and again in late April at $48.16. These are not panic sells; they look like an orderly PE sponsor walking down its position as the stock re-rates higher. The pattern is consistent with a company that came public with heavy PE ownership and is now broadening its institutional register. BlackRock has been adding — up 2.4m shares as of April 30 — and Voya, State Street, and Geode have all been building positions. The transition from KKR-controlled to broadly institutionally owned is quietly underway.

The next earnings event is scheduled for July 30. With two consecutive strong prints and a wall of analyst upgrades, the question heading into that date is whether margins can begin to widen or whether the revenue growth story demands another proof point before valuation re-rates further.